Risk Factors of Local Oropharyngeal and Laryngeal Adverse Effects from Use of Single Inhaled Corticosteroids and Long-Acting Beta-Agonists
Background: : Single inhaled corticosteroids and long-acting beta-agonists (ICS/LABA) are clinically effective and safe. However, if local oropharyngeal and laryngeal adverse effects (LOLAE) appear, adherence to the use of ICS is impaired. To minimize the development of adverse effects, it is essent...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2012-01-01
|
| Series: | Allergology International |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1323893015302598 |
| _version_ | 1818041353093775360 |
|---|---|
| author | Nobuyuki Horita Masako To Kosuke Araki Kosuke Haruki Yasuo To |
| author_facet | Nobuyuki Horita Masako To Kosuke Araki Kosuke Haruki Yasuo To |
| author_sort | Nobuyuki Horita |
| collection | DOAJ |
| description | Background: : Single inhaled corticosteroids and long-acting beta-agonists (ICS/LABA) are clinically effective and safe. However, if local oropharyngeal and laryngeal adverse effects (LOLAE) appear, adherence to the use of ICS is impaired. To minimize the development of adverse effects, it is essential to identify the underlying risk factors.
Methods: : The study included 481 asthmatic patients who were prescribed ICS/LABA for the first time in their life between January and September of 2010. Patients ranged in age from 14 to 86 years old and consisted of 281 never smokers and 200 smokers. All data were collected retrospectively by respirologists.
Results: : Seventy-three out of 481 patients suffered from one or more adverse effects, with 54 of these exhibiting LOLAE. Patients with LOLAE (51.4 ± 16.2 yrs) were significantly older than those without LOLAE (43.7 ± 15.9 yrs) (p = 0.0011) and were also prescribed a significantly higher dose of ICS. The pack-years of patients with LOLAE (2.1 ± 4.9) were significantly lowerthan those without LOLAE (6.0 ± 13.0) (p = 0.0087). The type of administered ICS was also significantly associated with a risk of developing LOLAE.
Conclusions: : Our survey indicated that a greater age, a higher dose of ICS, and the type of ICS were potential risk factors of LOLAE. The identified factors should be considered in a clinical setting in order to prevent the development of LOLAE and provide optimal treatment to patients. |
| first_indexed | 2024-12-10T08:29:04Z |
| format | Article |
| id | doaj.art-6936ec702a5c4ee284b433e810131ad1 |
| institution | Directory Open Access Journal |
| issn | 1323-8930 |
| language | English |
| last_indexed | 2024-12-10T08:29:04Z |
| publishDate | 2012-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Allergology International |
| spelling | doaj.art-6936ec702a5c4ee284b433e810131ad12022-12-22T01:56:08ZengElsevierAllergology International1323-89302012-01-0161458358810.2332/allergolint.11-OA-0396Risk Factors of Local Oropharyngeal and Laryngeal Adverse Effects from Use of Single Inhaled Corticosteroids and Long-Acting Beta-AgonistsNobuyuki Horita0Masako To1Kosuke Araki2Kosuke Haruki3Yasuo To4Department of Allergy and Respiratory Medicine, The Fraternity Memorial Hospital, TokyoDepartment of Allergy and Respiratory Medicine, The Fraternity Memorial Hospital, TokyoDepartment of Allergy and Respiratory Medicine, The Fraternity Memorial Hospital, TokyoDepartment of Laboratory Medicine, Dokkyo Medical University, Koshigaya Hospital, Saitama, Japan.Department of Allergy and Respiratory Medicine, The Fraternity Memorial Hospital, TokyoBackground: : Single inhaled corticosteroids and long-acting beta-agonists (ICS/LABA) are clinically effective and safe. However, if local oropharyngeal and laryngeal adverse effects (LOLAE) appear, adherence to the use of ICS is impaired. To minimize the development of adverse effects, it is essential to identify the underlying risk factors. Methods: : The study included 481 asthmatic patients who were prescribed ICS/LABA for the first time in their life between January and September of 2010. Patients ranged in age from 14 to 86 years old and consisted of 281 never smokers and 200 smokers. All data were collected retrospectively by respirologists. Results: : Seventy-three out of 481 patients suffered from one or more adverse effects, with 54 of these exhibiting LOLAE. Patients with LOLAE (51.4 ± 16.2 yrs) were significantly older than those without LOLAE (43.7 ± 15.9 yrs) (p = 0.0011) and were also prescribed a significantly higher dose of ICS. The pack-years of patients with LOLAE (2.1 ± 4.9) were significantly lowerthan those without LOLAE (6.0 ± 13.0) (p = 0.0087). The type of administered ICS was also significantly associated with a risk of developing LOLAE. Conclusions: : Our survey indicated that a greater age, a higher dose of ICS, and the type of ICS were potential risk factors of LOLAE. The identified factors should be considered in a clinical setting in order to prevent the development of LOLAE and provide optimal treatment to patients.http://www.sciencedirect.com/science/article/pii/S1323893015302598adrenergic beta-agonistsadverse effectsasthmaglucocorticoidsmetered-dose inhalers |
| spellingShingle | Nobuyuki Horita Masako To Kosuke Araki Kosuke Haruki Yasuo To Risk Factors of Local Oropharyngeal and Laryngeal Adverse Effects from Use of Single Inhaled Corticosteroids and Long-Acting Beta-Agonists Allergology International adrenergic beta-agonists adverse effects asthma glucocorticoids metered-dose inhalers |
| title | Risk Factors of Local Oropharyngeal and Laryngeal Adverse Effects from Use of Single Inhaled Corticosteroids and Long-Acting Beta-Agonists |
| title_full | Risk Factors of Local Oropharyngeal and Laryngeal Adverse Effects from Use of Single Inhaled Corticosteroids and Long-Acting Beta-Agonists |
| title_fullStr | Risk Factors of Local Oropharyngeal and Laryngeal Adverse Effects from Use of Single Inhaled Corticosteroids and Long-Acting Beta-Agonists |
| title_full_unstemmed | Risk Factors of Local Oropharyngeal and Laryngeal Adverse Effects from Use of Single Inhaled Corticosteroids and Long-Acting Beta-Agonists |
| title_short | Risk Factors of Local Oropharyngeal and Laryngeal Adverse Effects from Use of Single Inhaled Corticosteroids and Long-Acting Beta-Agonists |
| title_sort | risk factors of local oropharyngeal and laryngeal adverse effects from use of single inhaled corticosteroids and long acting beta agonists |
| topic | adrenergic beta-agonists adverse effects asthma glucocorticoids metered-dose inhalers |
| url | http://www.sciencedirect.com/science/article/pii/S1323893015302598 |
| work_keys_str_mv | AT nobuyukihorita riskfactorsoflocaloropharyngealandlaryngealadverseeffectsfromuseofsingleinhaledcorticosteroidsandlongactingbetaagonists AT masakoto riskfactorsoflocaloropharyngealandlaryngealadverseeffectsfromuseofsingleinhaledcorticosteroidsandlongactingbetaagonists AT kosukearaki riskfactorsoflocaloropharyngealandlaryngealadverseeffectsfromuseofsingleinhaledcorticosteroidsandlongactingbetaagonists AT kosukeharuki riskfactorsoflocaloropharyngealandlaryngealadverseeffectsfromuseofsingleinhaledcorticosteroidsandlongactingbetaagonists AT yasuoto riskfactorsoflocaloropharyngealandlaryngealadverseeffectsfromuseofsingleinhaledcorticosteroidsandlongactingbetaagonists |